Teyi Pharmaceutical Group Co Ltd (002728) — Tangible Net Worth Ratio
Teyi Pharmaceutical Group Co Ltd (002728) has a Tangible Net Worth Ratio of 92.1% as of March 2026. This metric is calculated by deducting intangible assets (CN¥146.73 Million) from net assets (CN¥1.85 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Teyi Pharmaceutical Group Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Teyi Pharmaceutical Group Co Ltd Tangible Net Worth Ratio (2009–2025)
This chart shows how Teyi Pharmaceutical Group Co Ltd's Tangible Net Worth Ratio has changed across 17 annual periods from 2009 to 2025. As of March 2026, the ratio stands at 92.1%, reflecting net assets of CN¥1.85 Billion with intangible assets of CN¥146.73 Million CNY. Also explore 002728 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Teyi Pharmaceutical Group Co Ltd (2009–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Teyi Pharmaceutical Group Co Ltd from 2009 to 2025, covering 17 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 002728 market cap.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 91.9% | CN¥1.84 Billion | CN¥148.77 Million | CN¥2.31 Billion | ▲ +0.8 pp |
| 2024 | 91.2% | CN¥1.76 Billion | CN¥156.04 Million | CN¥2.40 Billion | ▼ -0.7 pp |
| 2023 | 91.8% | CN¥2.01 Billion | CN¥164.64 Million | CN¥2.51 Billion | ▲ +3.6 pp |
| 2022 | 88.2% | CN¥1.40 Billion | CN¥165.23 Million | CN¥2.55 Billion | ▲ +1.9 pp |
| 2021 | 86.4% | CN¥1.26 Billion | CN¥172.15 Million | CN¥2.07 Billion | ▲ +1.7 pp |
| 2020 | 84.6% | CN¥1.08 Billion | CN¥166.19 Million | CN¥2.26 Billion | ▼ -0.8 pp |
| 2019 | 85.4% | CN¥1.15 Billion | CN¥168.58 Million | CN¥2.26 Billion | ▼ -2.5 pp |
| 2018 | 87.8% | CN¥1.11 Billion | CN¥135.09 Million | CN¥2.07 Billion | ▼ -5.4 pp |
| 2017 | 93.2% | CN¥1.04 Billion | CN¥70.67 Million | CN¥1.93 Billion | ▲ +1.6 pp |
| 2016 | 91.7% | CN¥886.57 Million | CN¥73.93 Million | CN¥1.60 Billion | ▲ +1.3 pp |
| 2015 | 90.4% | CN¥804.30 Million | CN¥77.31 Million | CN¥1.60 Billion | ▼ -7.3 pp |
| 2014 | 97.7% | CN¥735.64 Million | CN¥17.25 Million | CN¥825.60 Million | ▲ +2.7 pp |
| 2013 | 94.9% | CN¥350.14 Million | CN¥17.72 Million | CN¥453.54 Million | ▲ +1.3 pp |
| 2012 | 93.6% | CN¥285.34 Million | CN¥18.19 Million | CN¥388.22 Million | ▲ +1.9 pp |
| 2011 | 91.7% | CN¥225.51 Million | CN¥18.65 Million | CN¥283.21 Million | ▲ +2.9 pp |
| 2010 | 88.8% | CN¥170.81 Million | CN¥19.12 Million | CN¥252.73 Million | ▲ +7.6 pp |
| 2009 | 81.2% | CN¥103.18 Million | CN¥19.39 Million | CN¥189.65 Million | — |